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Introduction
In the National Research Council's (NRC) 2007 report, Toxicity Testing in the 21st Century: A Vision and a Strategy, they provided a general plan for a transition to a new "pathway-based" paradigm for toxicity testing and risk assessment (National Research Council, 2007) . This strategy envisions the replacement of in vivo animal toxicology studies with in vitro molecular studies, and the use of these in vitro studies in combination with computational models as the basis for regulatory decision making. In response, the U.S. Environmental Protection Agency (EPA) has developed its own strategic plan for moving towards a toxicity pathway-based risk assessment paradigm (U.S. EPA, 2009; www.epa.gov/spc/toxicitytesting) . Genomics data, resources, and tools are central to the execution of this future risk assessment paradigm. In addition, they are also useful within the current paradigm of risk assessment, especially in the context of formulating evidence-based extrapolations from one population to another and from one species to another. Indeed, one of the three key areas identified by a Health and Environmental Sciences Institute (HESI) survey in which genomics is perceived as having the greatest relevance and impact on toxicology is in the identification of species differences (Pettit et al., 2010) . Identifying and characterizing these interspecies differences is requisite to better informing the extrapolation of chemical risk across species, including from test animals to humans, and to understanding the uncertainties involved in this process.
There can be important differences among species in their response to chemical exposure, making the extrapolation of toxicological inferences from animal models to humans challenging in the context of human health risk assessment, and inferences across species challenging in the context of ecological risk assessment. These differences can be in dosimetry, exposure, metabolic pathways, and in homology of genes, proteins, biochemistry, and physiology (National Research Council, 2006) . Because of these challenges, there is a need for approaches to identify, understand, and, ideally, quantify interspecies differences in chemical mechanism of action. A chemical's mechanism of action is defined here as the complete molecular sequence of events between the interaction of the chemical with its target site(s) and observation of the outcome(s) (Fig. 1) . The mechanism of action can include both toxicokinetic (e.g., chemical absorption, distribution, metabolism, or excretion) and toxicodynamic events (e.g., changes at the molecular, cellular, tissue, or organ level). Because a chemical's mechanism of action has rarely been fully understood due to data limitations, the "mode of action" concept was developed for and applied to human health risk assessment. A chemical's mode of action, or "MOA," has been functionally defined as a key event, or a sequence of key events, that a particular toxicity outcome is dependent upon (i.e., part of the causal pathway and not a coincident event) (U.S. EPA, 2006) . However, increasing information on mechanism of action provided by genomic and toxicogenomic studies (for example, see the Comparative Toxicogenomics Database; ctd.mdibl.org) has revealed that numerous environmental chemicals have multiple MOAs, in some cases affecting multiple pathways. Therefore, we focus here on the types of genomics data, resources, and associated computational tools that show promise for characterizing interspecies differences in mechanisms of action, and that will thereby improve our understanding of the uncertainties 
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Fig. 1. Interspecies differences in chemical mechanism of action after environmental chemical exposure. Illustration of where differences between two species, rat and human, may exist in response to chemical exposure. Human and rat are shown as example species because these species are often compared in human health risk assessment; other species would be relevant examples for ecological risk assessment. Arrows with question marks represent potential biological differences in the toxicokinetic (TK) and toxicodynamic (TD) mechanisms, and in the potential health effect/outcome. (ADME = absorption, distribution, metabolism, and excretion.) There are multiple, different scenarios encountered for different chemicals in which some data on TK and/or TD are available for more than one species. For example, when comparing species for a chemical's mechanism of action where the outcome of interest is similar across species, the differences in mechanism of action could be at the TK and/or TD level.
inherent in extrapolating inferences across species in both human health risk assessment and ecological risk assessment. In regards to human health risk assessment, it is usually the case for a given chemical that there are limited data available to establish human relevance (e.g., epidemiological studies, human in vitro assays). In the absence of human data, the assumption that health effects observed in animal test models are similar to health effects in humans is employed by EPA (for example, neurotoxicity risk assessment guidelines (U.S. EPA, 1998) . Indeed, the current risk assessment paradigm often relies on data from high dose-based animal toxicological assays and on multiple extrapolations -from endpoints in one species to endpoints in another species, from high doses to low doses, and from one population to another. These extrapolated inferences about the health effects of chemicals are some of the sources of uncertainty inherent in risk assessment. Furthermore, like traditional toxicology studies, many of the computational toxicology models currently being developed, such as virtual tissue models, are also based on data from animal studies (www.epa.gov/ncct/virtual_liver; www. epa.gov/ncct/v-Embryo; Shah and Wambaugh, 2010) . For application to human health risk assessment, inferences based on these types of models will therefore also require extrapolating across species.
To transition to the NRC and EPA vision of toxicity "pathway-based" risk assessment, the development and adoption of methods for recognizing perturbations to pathways, for identifying "toxicity pathways," and for comparing effects of toxicity pathway perturbations across species will be crucial. It is expected that the increasing availability of genome-wide data, genomics tools, and molecular mechanistic data will enable the development of such methods, including new approaches for informing interspecies differences in chemical mechanism of action (National Research Council, 2006 Benson and Di Giulio, 2007) . To fully leverage the floodgate of molecular information that has opened in the past decade, environmental chemical risk assessors will need a toolbox of tested methodologies that can be used to inform interspecies differences. Currently, since environmental chemicals commonly lack a sufficient human data set, it can be difficult to assess the relevance of health effects observed in animal-based toxicology studies to human health risk assessment. Likewise, for species of concern in ecological risk assessments, approaches for better identifying differences, characterizing uncertainties, and extrapolating inferences about the toxic effects of environmental chemicals across multiple, differing species are needed.
To help advance research and development in this area of environmental chemical risk assessment, in this article we compare and contrast existing approaches that can be used, modified, and combined in new ways to discover and characterize interspecies differences in chemical mechanism of action. The focus of this article is on the critical review of the available comparative methods, and while some chemical examples are provided to highlight the use of some methods, this article does not include a comprehensive review of chemical examples. First, from disciplines as varied as evolutionary biology, systems biology, mathematics, and computer science, we compile and discuss methodologies for making simple to complex comparisons between and among sets of information. These methodologies can be applied to comparative analyses of molecules and molecular mechanisms, including comparisons across species of genomics data such as gene sequences, protein sequences, mRNA transcript abundance, protein-protein interactions, gene-protein interactions, etc. Second, we discuss the advantages and limitations of these various comparative approaches. Third, we assess some of the opportunities for applying these approaches within the current risk assessment structure, and we identify areas in need of further development for use in toxicity pathway-based risk assessment.
Approaches to comparing species at the molecular level
In human health risk assessment, we often need to extrapolate inferences about biological function and impairment thereof from non-human animals to humans, with the end goal of understanding the human health impacts of environmental contaminants. The mechanistic differences in responses to chemicals among different species can occur at any point along the different levels of biological organization in the continuum from exposure to endpoint (Fig. 1) . To improve interspecies extrapolations in risk assessment and to reduce and characterize their associated uncertainties, we therefore need the ability to compare these differing biological levels of information across species. Thanks to genomics, bioinformatics, and computational algorithms from various fields, this ability exists. The data from genome projects and the tools of molecular biology have greatly expanded our discovery and understanding of physiological traits on a cellular and molecular basis, also enabling the examination of chemical perturbations on these differing biological levels of organization (Mattes, 2006) . And, the conceptual framework of evolutionary biology plus mathematical algorithms from graph theory and complex network theory have provided the theoretical underpinnings and computational mechanisms needed for making comparisons and inferences across species. Here, we provide a compilation and overview of existing approaches that can be utilized for interspecies comparisons of genomic information. These approaches were developed within varied disciplines for varied purposes but are binned here by their relevance to differing levels of biological complexityfrom genes and proteins to pathways to complex biological networks.
Gene/protein level approaches
Scientific comparisons across species in biology started with attempts to classify organisms based on their overall similarity of observable traits, typically morphological traits. This comparison of shared physical characteristics across species, known as phenetics, has largely been superseded by cladistics (Hennig, 1965) , in which shared derived characters are compared to infer the evolutionary relationships among organisms. These relationships are depicted by cladograms, or evolutionary trees. As it became possible to reconstruct evolutionary relationships among species using molecules as characters, cladistic analysis using comparisons of DNA, RNA, and protein sequences (molecular phylogenetics) became the norm for testing taxonomic hypotheses. Therefore, the earliest and simplest molecular methods of inter-species comparisons were developed at the level of proteins, genes, and non-coding DNA sequences.
The computationally intensive nature of aligning, analyzing, and reconstructing evolutionary trees from molecular sequence data of multiple species gave rise to various computational sequence alignment and phylogenetic analysis methods. Because the processes of identifying the optimal multiple sequence alignment and/or the optimal tree can be prohibitively computationally expensive, these methods typically employ heuristic algorithms and scoring functions. A plethora of computer programs have been developed for both multiple sequence alignment and for phylogenetic tree reconstruction; for a fairly comprehensive listing of available programs and servers, see evolution.genetics.washington.edu/phylip/software.html. Some phylogenetic analysis methods, such as maximum parsimony, implicitly invoke an evolutionary model; some, such as maximum likelihood and Bayesian inference, explicitly employ models of evolution; and others, such as neighbor-joining, are based on genetic distance measures typically calculated using population genetics models of genetic mutation versus genetic drift, or percent sequence similarity (for reviews of phylogenetic methods, see Nielsen, 2005;  and also see Yang, 2006) . In addition, further advancing our abilities to make comparisons among species at the molecular level are the more recent technological breakthroughs that have given rise to highthroughput genome sequencing, and the availability of genomics data through open access online databases (see Table 1 ).
In the simplest scenario, the biological unit of interest for interspecies comparisons at the molecular level is a DNA sequence such as a gene, or a protein sequence (see Frazer et al., 2003 for a review of methods). For example, given a gene or protein known to be involved in the mechanism of action of a toxicant in rats, we could compare its sequence to the sequence of its orthologous gene/protein in humans. Orthologs are genes/proteins in different species that originated from a common ancestral gene/protein separated by a speciation event, as opposed to genes or proteins that are derived from gene duplication events within a species. The usefulness of an ortholog comparison approach for risk assessment lays in an assumption that evolutionary conservation of a gene or protein sequence correlates with conservation of its function, which in turn corresponds to a conserved mechanism of action. Ortholog comparisons have proven useful in drug target prediction in the field of pharmacology (Searls, 2003; Gunnarsson et al., 2008) . However, while evolutionarily conserved sequences are likely functionally conserved as well, recent analyses of genomic data have revealed that many sequences serving a conserved function are not themselves conserved (Margulies et al., 2007; Monroe, 2009; Wang and Zhang, 2009 ). Therefore, while there is support for the assumption that highly evolutionarily conserved DNA and protein sequences reveal a selective constraint that belies an important and preserved function, the absence of conserved sequence across species does not guarantee the absence of a conserved function. In other words, while conserved sequences and high non-synonymous to synonymous substitution rate ratios in proteins are good indicators of natural selection that is maintaining a function by 'constraining' sequences from diverging over time, natural selection and the functional constraints it imposes may not always be evident by examination of gene and protein primary sequence information.
Since our goal is to make inferences across species about the function and/or relative expression of a gene or protein and, thereby, its role in the mechanism of action of a toxic agent, indices of overall sequence similarity, such as percent sequence similarity or percent identity (PID) (Raghava and Barton, 2006) , are of limited practical use as stand alone methods. Put another way, although gene and protein sequence similarity between species are quantifiable, such measures do not provide insight into differences in the function of those genes and proteins and how they may or may not affect the mechanism of action. Targeted approaches that compare changes within functional domains, protein structure, or gene regulatory sites, in addition to methods that compare changes in levels of protein expressed, are more likely to be useful in extrapolating inferences about gene and protein function across species. Of course, in cases of genes and proteins with known roles in xenobiotic metabolism or other well-studied disease processes, interspecies sequence differences among orthologs may already be documented and understood (see Mattes, 2006 for a review), and thus could be used in risk assessment. For example, the pesticide vinclozolin is known to act as an anti-androgen, binding to the androgen receptor (AR), thereby inhibiting androgen action by blocking binding of AR with endogenous androgens. Since this and other chemicals have been found to have such specific effects on one protein, approaches that compared the AR sequence and its binding affinity across species have been fruitful Wilson et al., 2007) . In the absence of such information, several in silico methods for determining the structure and assessing the functional importance and functional similarities of proteins have been developed.
Because conserved sequences are good indicators of natural selection, several methods of comparative sequence analysis have been developed to find these conserved sequences across genomes and, by inference, identify functionally important regions. Regions of DNA identified this way include both protein-coding and non- Simon et al., 2002) ; another type develops statistically rigorous single-site measures of evolutionary conservation using maximum likelihood analysis and models of nucleotide substitution (e.g., the "Genomic Evolutionary Rate Profiling" (GERP) of Cooper et al., 2005; Goode et al., 2010) ; and yet another type makes use of hidden Markov models whose parameters are estimated from multiple alignment by maximum likelihood. Finally, by integrating the results of several such alignment and conservation-detecting approaches, Margulies et al. (2007) showed that robust annotations of selectively constrained genomic regions could be produced.
As already mentioned, and as found to be true for the toxicologically important nuclear receptor PXR (pregnane X receptor) (LeCluyse, 2001; Moore et al., 2002; Mattes, 2006) , some proteins maintain a conserved function across evolutionary time without maintaining highly conserved primary sequences. To find these types of proteins, Barthet and Hilu (2008) developed an approach that identifies putative functional domains within rapidly evolving protein sequences. Their method evaluates the constraint on amino acid side chain composition across the open reading frames among multiple species. The basic assumption of this approach is that functional conservation across species is indicative of selective constraints on function; and, if selection is not acting on and therefore not evident in the primary DNA or amino acid sequence of a functionally conserved protein, then it must be acting on another level, such as on protein structure or on the physicochemical properties of particular amino acids. Additional methods for comparing the physicochemical variation at individual amino acid sites in proteins had previously been developed in the context of predicting the functional impairment or difference in function of proteins. Such methods either qualitatively examine (e.g., SIFT -Sorting Intolerant From Tolerant; Ng and Henikoff, 2003; Kumar et al., 2009) or quantify (e.g., MAPPMultivariate Analysis of Protein Polymorphism; Stone and Sidow, 2005 ) the physicochemical variation and functional impact of amino acid differences at each site in orthologous proteins using multiple species sequence alignments and, in the case of MAPP, evolutionary trees inferred from them to control for phylogenetic correlation.
Finally, in addition to comparing primary sequences and the physicochemical properties of protein residues, it is possible to directly compare the three-dimensional (3D) structures of proteins to infer differences in function across species. A number of algorithms that automate protein structural alignment and comparison using a variety of criteria have been developed (e.g., Taylor and Orengo, 1989; Falicov and Cohen, 1996; Shindyalov and Bourne, 1998; Jewett et al., 2003) . Examples of online resources that implement such algorithms, find and predict protein structures, and make 3D comparisons include: the Structural Classification of Proteins (SCOP) database (scop.mrc-lmb.com.ac.uk/scop) (Murzin et al., 1995; Lo Conte et al., 2000; Andreeva et al., 2004; Andreeva et al., 2008) with its associated collection of manually curated structural alignments, SISYPHUS (Andreeva et al., 2007) ; the ASTRAL Compendium for Sequence and Structure Analysis (astral.berkeley.edu) Chandonia et al., 2002 Chandonia et al., , 2004 ; MATRAS Protein 3D Structure Comparison (biunit.naist.jp/matras/) (Kawabata, 2003) ; and, MinRMS: A Tool for Determining Protein Similarity (www.cgl.ucsf.edu/research/ minrms) (Huang et al., 2000; Jewett et al., 2003) . Additional tools and resources can be found on the RCSB Protein Database (RCSB PDB) archive (www.pdb.org) (Berman et al., 2000) . However, most of these protein structure comparison methods were created at a time when structural analysis was the primary means of determining homologies between remotely related proteins. Due to the explosion of genomics technologies and sequence databases, protein homologies are now most efficiently determined based on sequence analysis. Indeed, even the SCOP database now relies on integrating sequencebased information into their protein comparison and classification scheme (Andreeva et al., 2008) . Additionally, there is some evidence that the functional domain architecture of proteins is more likely the result of evolutionary descent, or phylogenetic legacy, than selection for function (Gough, 2005) . This implies that methods incorporating the evolutionary relationships among proteins being compared will fare better in the context of understanding functional similarities and differences than comparisons based on structure alone. Therefore, 3D protein comparison across species is not currently a very useful approach for informing interspecies similarities and differences in protein function.
Chemical examples.
To predict human effects, a number of studies have performed genomic assessments of the interspecies differences in liver toxicity, a common side effect of certain pharmaceuticals and chemicals. One chemical example is the pharmaceutical, acetaminophen, which can be hepatotoxic and can cause death when used at overdose. The mechanism of action for the hepatotoxic response has been investigated in genomic studies in a number of species including human cells (reviewed in Mattes, 2006) . The hepatotoxicity is thought to be a result of exposure to the acetaminophen metabolite, N-acetyl-p-aminophenol (APAP). To identify a hepatotoxic genomic signature, Beyer et al. (2007) conducted a multicenter investigation comparing genomic changes induced in rat and mice livers (in vivo) by the hepatotoxic APAP and by a non-hepatotoxic APAP isomer (N-acetyl-m-aminophenol). They found that the hepatotoxic genomic signature includes c-Myc induction and further, developed a species-independent (i.e., in common to rat and mice) genomic signature relevant to liver necrosis that includes effects on c-Myc and Jun oncogenes. Their findings suggest some similarities in the mechanism of action between rat and mice but fails to discuss possible differences in the mechanism of action since the study did not present the rat and mouse differences in gene expression. Another chemical with hepatotoxic side effects, coumarin, was studied using an approach called an "informational bridge" to connect gene expression responses in in vitro rat hepatocytes, in vitro human hepatocytes, and in vivo rat livers (Uehara et al., 2010) . First, Uehara et al. (2010) identified "in vivo-in vitro bridging probes" from the rat data. Then these probes were assigned to their human orthologous genes to identify "rat-human bridging probes" which were used to study coumarin-induced gene expression changes in human hepatocytes. The pattern of changes in 25 genes was found to be similar between rat and human cells but the degree of change was greater in the rat.
Another type of comparative genomics study that focuses on interspecies comparisons of sequence-based functional elements was utilized to identify and compare human, mouse, and rat dioxin response elements (DREs) (Sun et al., 2004) . 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD; dioxin) mediates its effects via the aryl hydrocarbon receptor (AhR); dioxin binds to the AhR and alters the regulation of AhR-mediated genes. In this study, DRE-containing genes were identified and compared across species to identify common genes. The analysis found that DRE-regulated genes differed more between rodents and humans than between the two rodents. These studies provide examples of real-world interspecies comparative strategies, employed in pharmaceutical development and environmental toxicology, to predict human effects.
Pathway level approaches
Both adaptive (functional) and non-adaptive (neutral) evolutionary divergence can cause differences among species, but such differences in single genes are not typically representative of the complexity of a trait, since very few traits are monogenic. In other words, in most cases, multiple genes and regulatory elements interact with each other and with environmental factors to produce a phenotype. Therefore, using interspecies comparisons of a single gene or protein as a proxy for a phenotype of interest may be an overly simplistic method for extrapolating information from one species to another. It has therefore been postulated that molecular pathway comparisons will more accurately reflect similarities and differences across species in complex phenotypes such as those involved in toxicity endpoints (National Research Council, 2009) . A molecular pathway can be generally defined as a series of linked biochemical steps involving genes, proteins, and other biochemical factors whose activity results in the ebb and flow of molecules that lead to a biological effect. Any type of pathway, such as a metabolic pathway like the fatty acid synthesis pathway or a signaling pathway like the insulin receptor pathway, that is involved in the mechanism of action of a xenobiotic and can potentially lead to an adverse outcome, can be considered a "toxicity pathway". Therefore, comparisons of these pathways may be more informative biological levels for understanding the implications of interspecies extrapolation than single genes or proteins.
The most basic approach to pathway comparison is based on the presence or absence of orthologous proteins across species without regards to the direct interactions among the proteins. This approach was developed to predict the function of uncharacterized proteins, based on the assumption that proteins that co-occur across organisms likely function together, and that these clusters of proteins correspond to biologically meaningful pathways. Original presence/absence methods conduct a cluster analysis of organism-by-protein matrices that are either based on simple presence/absence binary data (i.e., 1 = protein present in that organism; 0 = protein absent) (Pellegrini et al., 1999; Liao and Noble, 2002; Wu et al., 2003) or that are modified by a measure of sequence similarity represented as continuous data (Date and Marcotte, 2003; Jothi et al., 2007) . Improvements to the basic presence/absence methods extend those approaches from comparisons of co-occurring proteins to comparisons of co-evolving proteins. By incorporating the evolutionary relationships among the species being compared into their algorithms (Barker and Pagel, 2005; Zhou et al., 2006; Barker et al., 2007; Cokus et al., 2007) , these methods provide additional information on the gain or loss of proteins in an evolutionary context. A related approach, also developed for the characterization of proteins and discovery of pathways, is based on comparing the size of gene families across species. As with the presence/absence approaches, some of these gene family size methods are correlationbased (Ranea et al., 2007) and others are coevolution-based (Cordero et al., 2008; Ruano-Rubio et al., 2009 ). Finally, there are analogous approaches that use binary presence/absence data, but that tally the presence/absence of other factors instead of tallying the pathway proteins. For example, Tun et al. (2006) analyze the presence/absence of interactions between the proteins, while Kastenmuller et al. (2009) and Gonzalez and Zimmer (2008) developed algorithms that compare pathways based on the presence/absence of phenotypes, including continuous, or quantitative, phenotypes. The latter two methods were developed to understand the biochemical basis of phenotypic traits, and they work by linking phenotypes to associated metabolic processes. Because toxicity endpoints are phenotypes, this method has potential for discovering and informing differences in toxicity pathways across species.
Unlike most of the aforementioned approaches, other types of interspecies pathway comparison take into account the interactions, or reactions, among the enzymes and compounds in the pathways being compared. One such approach analyzes the interacting functional domain patterns in protein-protein interactions across multiple species (Chen et al., 2008 ) -domains being the structural and functional units of proteins. The assumption underlying this method is that shared interacting domain patterns across species are indicative of shared functions; and according to the authors, this method achieves better than 95% accuracy at predicting gene function in humans. However, most of the approaches incorporating interaction information into interspecies pathway comparisons were not developed not as a means to predict and characterize the functionality of proteins and pathways. Most were created as an additional means to uncovering the evolutionary relationships among organisms, and especially among microbes whose evolutionary relationships can be intractable to standard sequence-based phylogenetic analyses due to the complicating factor of horizontal gene transfer. Approaches were therefore developed that attempt to reconstruct robust phylogenetic trees using functional pathway information (Heymans and Singh, 2003) . These approaches typically model their molecular pathways as graphs (see Deville et al., 2003 for overview of graph models), align the graphs across one or more species, and then assess and score the similarity among the graphs in one way or another. For example, one web server (www.jaist.ac.jp/ clemente/cgi-bin/phylo.pl) (Clemente et al., 2007) graphs comparisons of pathway structure using different measures of protein functional similarity: measures based on enzyme class (hierarchical similarity) (Tohsato et al., 2000; Chen and Hofestadt, 2004) , information content similarity (Tohsato et al., 2000; Pinter et al., 2005) , or gene ontology similarity (Clemente et al., 2005) . It pulls pathways from the KEGG database (www.genome.jp/kegg/pathway.html) and currently allows for comparison across 13 species including mouse, rat, and human. Other approaches assume that functional similarities are inherent in primary sequences and so use a measure of sequence similarity from either pairwise (Ovacik and Androulakis, this issue) or multi-species sequence alignments Schulten, 1999, 2001) to compare topologically aligned pathway graphs. Even though many of these approaches were developed for studying evolution in microbes, their potential usefulness to risk assessment is in providing the capacity to align and compare pathways across species, regardless of the taxa.
Methods that highlight the differences between species in their use of similar pathways and similar reactions within pathways may be especially useful for informing interspecies differences in toxicity pathways. One such method, the Metabolic Pathway Alignment and Scoring (M-PAS) method, is another graph alignment approach but is based on discovering conserved pathways from "building blocks" of aligned reactions that account for reaction direction (Li et al., 2008) . This method integrates enzyme function and sequence similarity scores into one similarity score and aligns networks of these building blocks, resulting in aligned pathways with quantified levels of conservation, giving insight into the differences between species. Although currently limited to two-species comparisons and to linear (acyclic) pathways, Li et al. (2008) suggest the M-PAS can be expanded to more complex graph topologies and to multi-species comparisons.
Chemical example.
In mice, PPARα regulates hepatic lipid metabolism, but there is an absence of data on the mechanism of PPARα in humans. To address data gap, Rakhshandehroo et al. (2009) compared gene level and pathway level approaches by assessing the genomic response in primary hepatocytes exposed to the PPARα agonist pharmaceutical, Wy14643. Their comparison of mouse and human hepatocyte (in vitro) responses found little overlap at the gene level but a greater overlap at the pathway level. Common pathways included lipid metabolism and known PPARα target pathways (e.g., HMGCS2). In addition, human specific PPARα-regulated pathways for xenobiotic metabolism and apolipoprotein synthesis were identified. Their results suggest some common and some divergent liver responses to PPARα between rat and human. Identification of such human-specific and in-common pathway effects can improve our knowledge about species-specific mechanistic steps and aid the prediction of human health effects.
Network level approaches
Even pathways are relatively simplistic models of extremely complex biological processes. In reality, pathways overlap, interact with each other, and are components of highly complex non-linear molecular networks (see Wuchty et al., 2006 for a review of biological network architecture). The nodes of molecular networks typically represent molecular entities like genes, proteins, mRNA levels, or metabolites, and the edges connecting these nodes represent the functional relationships among those entities, such as protein-protein interactions, gene modifications, transcriptional regulation, etc. (Han, 2008; Schadt, 2009) . Complex traits, including common human diseases, originate from more than single gene disruptions; they stem from a complex interaction between an organism's molecular networks (genetic and epigenetic) and a broad array of environmental factors including exposure to environmental toxic agents. Recent research in systems biology has shown that molecular networks both respond to and, in effect, cause common human disease through perturbations to complex interconnected molecular interactions; and that therefore, they may be more relevant to understanding diseases than are a small number of genes or single pathways (Chen et al., 2008; Schadt, 2009 ). Because of this, comparisons of entire molecular networks and/or of interacting sub-networks underlying or associated with toxicological endpoints should provide yet another method for informing interspecies differences in a risk assessment context.
Approaches to interspecies network comparison share similarities with methods used for pathway comparison, since both involve graphical models. However, additional challenges not encountered by most pathway comparisons include the non-linear structure of networks, the exponential growth of the size of the alignment graphs with increasing number of aligned networks, and the dynamic nature of networks (Han, 2008) . In addition, molecular networks are not static; they have "dynamic modularity" in that they can vary over time and space (Kholodenko, 2006; Han, 2008) . Nevertheless, several approaches to network comparison have been developed recently and, as occurred within the now mature field of sequence alignment, improvements in this area are expected to continue progressing quickly. In regards to interspecies network differences, there are two general types of relevant network comparisons: network alignment approaches, including global and local network alignment as well as network querying (see review by Sharan and Ideker, 2006) , and clustering approaches.
Global and local network alignment involve the comparison of two or more networks and have mainly been used to elucidate network structure and to identify sub-networks conserved across species and therefore likely to represent functional biological units. Network querying, on the other hand, is analogous to searching a sequence database for a match to an input sequence; it involves graph-mining techniques that search for sub-networks similar to the input query in a given network or network database. These methods could be useful for informing interspecies differences in the context of chemical risk assessment both by enabling the discovery of homologous network structures and by aiding in the identification of orthologous proteins, orthologous protein-protein interaction pairs (interologs), and signaling and regulatory pathways across species.
Network alignment and querying algorithms consist of scoring functions and search algorithms. Most network alignment approaches developed to date conduct global network comparisons by scoring the homologous node pairs and their interactions, constructing network alignment graphs from these, and then searching these sets of graphs for the highest scoring alignments (e.g., Koyuturk et al., 2004; Sharan et al., 2005a Sharan et al., , 2005b Flannick et al., 2006; Pinney et al., 2007) . These two essential parts of network alignment -a scoring framework that represents current knowledge pertaining to the network's entities and evolution, plus an algorithm for the rapid identification of conserved alignments from an exponentially large set of possible alignmentsare problems with multiple solutions. For example, one solution to the scoring problem uses a probabilistic function (e.g., PATHBLAST: Kelley et al., 2003) , while another employs an overall confidence score based on the combined statistical significance of sequence similarity, number of conserved interactions, and functional relatedness (e.g., HopeMap: Tian and Samatova, 2009) , and yet others adopt evolution-based scoring (e.g., MaWISh: Koyuturk et al., 2006; and, Graemlin: Flannick et al., 2009) or incorporate probabilistic models of evolution (e.g., Berg et al., 2004; Berg and Lässig, 2006; and , CAPPI: Dutkowski and Tiuryn, 2007, 2009) . Continued improvements to scoring functions, including more phylogeny-based approaches, are expected as our understanding of molecular network evolution increases.
As with scoring functions, several approaches to the problem of the search algorithm have been developed. However, while the scoring problem is in the realm of statistics, probability, and evolutionary and molecular biology, the search algorithm problem sits squarely in the fields of graph theory and in the latest extension of graph theory: complex network theory. Solutions to the search problem have to address the issues of speed, scalability, and accuracy. Most current solutions to the search problem include approaches, such as progressive alignment, that use a stepwise, iterative algorithm for finding locally optimal solutions based on the score (a "greedy heuristic"). A heuristic is employed because the growth of the alignment graphs is a limiting factor in terms of computational cost. Indeed, one large hurdle for many of these approaches has been in scaling up beyond pairwise comparisons (Kelley et al., 2003; Koyuturk et al., 2004 Koyuturk et al., , 2006 Sharan et al., 2005a; Zaslavskiy et al., 2009 ) to multi-species network comparisons (Sharan et al., 2005b; Flannick et al., 2006 Flannick et al., , 2009 Alexeyenko and Sonnhammer, 2009; Dutkowski and Tiuryn, 2009; Qian and Yoon, 2009; Tan et al., 2009 ). In addition, a non-heuristic pairwise comparison solution to the search algorithm problem has also recently been proposed by Klau (2009) . According to the author, this algorithm is adaptable to many types of networks and is scalable to multi-network comparisons; it works by mathematically redefining the global alignment graph in such a way that a search for the optimal structural alignment is possible.
Creative modifications of these approaches, as well as alternatives to network alignment approaches, have also recently been developed. For example, whereas most alignment graphs are composite graphs in which nodes are merged representations of orthologous relationships among molecules like genes and proteins connected by edges representing interactions, there are network alignment approaches that instead define the nodes as the interactions or as sets of interactions. One such approach, the "direct-edge-alignment" method, uses domain-domain interactions across two networks to construct alignable pairs of edges and thereby directly infers a protein-protein interaction network (DOMAIN: Guo and Hartemink, 2009) . Another approach creates networks of interacting pathways where the nodes are pathways and the edges between them are the compounds they exchange or share (Mazurie et al., 2008) . On the other hand, network comparison approaches that do not even use network alignment to address interspecies questions have also been developed. Because network alignment can be limited in coverage if dependent on orthologous relationships, and because it is potentially sensitive to errors in network topology, some investigators have instead relied on graph clustering algorithms for comparisons across networks. For example, there are connectivity-based clustering approaches (e.g., Bergmann et al., 2003; Yamada et al., 2006; Narayanan and Karp, 2007; Borenstein et al., 2008; Erten et al., 2009; Wiles et al., 2010) , data integration clustering approaches (Kelley and Ideker, 2005; Linghu et al., 2008; Alexeyenko and Sonnhammer, 2009; , and probabilistic clustering approaches (Stuart et al., 2003) that have successfully combined and compared a variety of data types across multiple species. In addition, at least one approach integrates network alignment methods with graph clustering algorithms to compare protein functional similarity across species (Ali and Deane, 2009).
Discussion
The tools and concepts of comparative genomics, including genome-wide measurements of biological entities such as proteins, expressed genes, metabolites, and DNA methylation (i.e., proteomics, transcriptomics, metabolomics, and genomic methylation), have the power to greatly enhance toxicology and risk assessment. Comparative genomics can provide a means for identifying toxicity pathways, mechanisms, and biomarkers, and their differences across species. In the toxicity pathway-based approach to risk assessment, with its envisioned transition to a greater reliance on in vitro assays, comparative genomics will be crucial for establishing mechanistic links and quantitative relationships between laboratory animal studies and human cell-based in vitro assays. Thus, the comparative genomics and computational approaches compiled here will be critical to addressing one of the challenges in human health risk assessment: reducing the uncertainty caused by extrapolated inferences about toxicological exposure and health effects from test animals to humans (Fig. 1) .
It is beyond the current state of the science to produce a guide on using genomics for extrapolating inferences across species in environmental chemical risk assessment. Instead, by categorizing the different types of approaches, starting with interspecies comparisons at the relatively simplistic level of genes and proteins and ending with comparisons at the systems biology level of molecular networks, we have presented an overview of the main types of approaches available to researchers (Fig. 2) . We also provide examples of several widely used genomics databases and publicly available interspecies comparison tools and resources in Tables 1 and 2 respectively. In this section, we evaluate the strengths and weaknesses of these major types of interspecies molecular comparison approaches in terms of their potential for implementation in risk assessment. Furthermore, we discuss the challenges and overarching recommendations for research that will help bridge the gap between current comparative genomics approaches and application to risk assessment.
Strengths and weaknesses of approaches
Even though the quantity of available molecular information for different species is increasing rapidly, we face a variety of technical and experimental issues when using these data in interspecies comparisons. Genome-wide data are full of noise (false positives) and annotation from one species to another can be unreliable. Annotation of genomes and experimental arrays, as well as the availability of genomic data and experimental platforms, are technical issues that impact quantity, quality, and completeness of data sets. With pathway and network comparisons in particular, we have to deal with this dilemma of incomplete data sets when evaluating whether or not the comparisons accurately represent the systems being modeled. For example, given a protein-protein interaction network, if the set of interactions being examined is incomplete, then the absence of an observation assumed to indicate non-interaction is potentially erroneous. In addition to incomplete data sets, we also have the problem of inconsistent experimental conditions across studies. Differences across studies in coverage of genome-wide assays, in experimental design, and in analyses can impact conclusions drawn when comparing results from such studies. Therefore, comparison methods that are robust to data gaps and inconsistencies such as these are needed. To account for shortcomings in a way that is useful in the context of risk assessment, performance estimates of the models and comparison approaches used will be critical.
Of all levels of interspecies molecular comparison, the comparison of single entities such as DNA sequences, protein functional domains, whole protein structures, or even single amino acid mutations, has the longest history and therefore is the best-tested set of methodologies. Sequence comparison methods are robust, well-understood, and widely used. While minor issues with ascertaining orthology do pertain to these approaches, they do not suffer from the larger problem of incomplete datasets. In addition, techniques to predict functional changes based on sequence or structural differences have proven useful in hypothesis generation and weight-of-evidence schema in the context of gene characterization and discovery. However, it is not easy to predict how a functional change in a sequence, such as an enzyme critical to the mechanism of action, may impact a toxicological outcome. Although the reductionist approach is comfortable and attractive in both science and risk assessment, the isolation of complex biological problems, like toxicity, to the level of a gene or protein may mean missing the mark more often than not. In other words, Fig. 2 . Molecular-based interspecies comparisons. Simplified depiction of three levels of molecular comparisons for extrapolating inferences about mechanism of action across species (showing rat and human as examples) using comparative genomics. In reality, pathway models tend to involve more nodes and interactions than depicted, and may also have non-linear components; in addition, molecular network models using genome-wide data will be far more complex in terms of nodes and interactions/ linkages than depicted in the cartoon above, giving them the appearance of "hairballs".
these small entities do not exist and operate in isolation; their connections and interactions with other molecules may have ramifications beyond their perceived functional change; or on the other hand, their connections and interactions could provide resiliencya damping of effects. However, in addition to computational comparisons of genes, proteins, and other sequences from genomic datasets, there are also targeted experimental approaches that can address and help quantify interspecies comparisons at this biological level of organization, such as relative expression, gene knock-down, and enzyme activity assays (see Benson and Di Giulio, 2007 for overview) . Because of this, we expect that many initial attempts to incorporate interspecies molecular comparisons into risk assessment and to quantify differences will be attempted at this level.
More biologically relevant modeling of toxicological perturbation will happen at the level of pathways and networks. These "systems" may have resiliency and may have weaknesses that are not evident in comparisons of single gene or protein differences. Pathway comparisons fit nicely into the NRC envisioned framework of toxicity pathway-based risk assessment. They provide a physiological context for protein and gene changes in a model that may better capture the key events of a mechanism of action. Approaches for comparing pathways and for measuring conservation of pathway function are still developing and are still mainly being used for understanding prokaryote evolution. While such approaches provide the structure needed for interspecies pathway comparison and are becoming better at extracting information about evolutionary relatedness based on functional systems, they do not yet encode a means for quantifying functional changes or their physiological implications.
Networks are a natural extension of pathway models; they are as unbiased a molecular representation of a biological system as is possible. In addition, because pathways are essentially simplified networks, there is no reason that network comparison approaches cannot be applied to them -there simply has been a separation of goals driving the two approaches. Networks can model anything we can measure including the functional relationships among molecules such as: gene modifications, protein-protein interactions, transcriptional regulation, DNA methylation, pre-and post-translational modifications, metabolic reactions, siRNA-mRNA interactions, etc. Because molecular network models of genome-wide processes are all-encompassing in nature and constructed from unbiased empirical Table 2 Selection of publicly available online tools for interspecies molecular comparisons.
Tool/resource Description data, and because they display an evolved robustness to perturbations (Albert et al., 2000; Wuchty et al., 2006; Zhu et al., 2007; Costa et al., 2008) , molecular networks are the most comprehensive and biologically relevant models available for understanding physiological responses to environmental chemicals and are expected to greatly enhance 21st century risk assessment (Edwards and Preston, 2008) . However, among the approaches discussed here, interspecies network comparisons have the potential to suffer the most from the problem of incomplete information resulting from disparities in availability and annotation of data across, as well as within, species. Nevertheless, a low percentage of missing or mis-annotated pieces of information from a complex model of a biological system such as a molecular network, are less likely to affect overall analyses and conclusions than are the unknown and missing data left out due to the simplicity of models such as comparisons of cherry-picked genes and proteins.
Challenges and recommendations for risk assessment
The interspecies comparison approaches compiled and discussed here were all developed for purposes other than risk assessment, such as for inferring evolutionary relationships, for predicting functional sequences and conserved pathways, for hypothesis generation in finding and testing disease-related processes, etc. The integration of genomics-based approaches such as these with in vivo and in vitro toxicity testing data will enhance the identification of toxicity pathways, improve our understanding of similarities and differences in mechanism of action among species, and will also aid in the development of virtual tissue models. A major challenge for the future paradigm of human health risk assessment is in translating approaches like these into ways of extrapolating inferences qualitatively, and ultimately quantitatively, about toxicological outcomes from test animals to humans. Addressing this challenge will require the development of genomics-based risk assessment methods. We propose that, with further refinement and testing, computational interspecies comparison approaches, such as those discussed here, can be adapted for this use.
Additionally, molecular data can be incorporated into the current paradigm of risk assessment as well. Information on molecular differences between test animals and humans can be applied qualitatively by using a weight-of-evidence approach to judge whether or not to adjust the interspecies uncertainty factor (Box 1) and/or whether or not the animal data are relevant to humans. Data from gene/protein, pathway, and network comparisons could contribute to the weight of evidence about interspecies differences for a mechanism of action that may already include, for instance, known differences in the outcomes and/or regulation of the outcome across species. For example, in the case of chemicals that affect androgen action, extensive information known about the regulation of male sexual differentiation by androgens across vertebrates (Hotchkiss et al., 2002; Wilson et al., 2004 Hartig et al., 2007) would be part of the weight-ofevidence that, combined with gene, pathway, and/or network findings, may inform a picture of high or low similarity of the mechanism of action across test species and humans. In this qualitative application, the degree of change in the interspecies uncertainty factor would be based on scientific judgment and precedent. Indeed, current and future risk assessment decision-making processes are based, in part, on scientific judgment after weighing multiple factors including data sources, data coverage, data quality, and exposure scenarios.
The larger challenge is in coming up with methods to utilize the findings of these comparative approaches in a quantitative manner. For example, while interspecies differences between gene and protein sequences are easy to quantify, the functional differences and phenotypic differences they may or may not cause are not easy to quantify. This difficulty in quantifying functional and phenotypic divergence can then be exacerbated by a lack of information on the relative importance of the genes or proteins to the chemical mechanism of action. On the other hand, less reductionist approaches, such as those involving pathway and network comparisons across species, show more potential for eventual quantitative application to risk assessment, because they have the capacity to measure perturbations on a systems level. However, for quantitative application, methods shown to be robust to data gaps and data inconsistencies and that include performance estimates are still needed.
Even without methodologies refined specifically for application to risk assessment, interspecies network and pathway perturbation models based on existing methods can be used now to generate testable hypotheses for human cell-based in vitro assays that can then be used qualitatively, and eventually quantitatively, in risk assessment. For example, as illustrated in Fig. 3 , given chemical X with known adverse outcomes in rat in vivo studies: first, a rat network perturbation model could be developed; second, the rat and human networks could be compared; third, based on differences and similarities highlighted by the interspecies network comparison, human in vitro assays could be developed and performed; fourth, in vitro perturbations could be mapped back to the compared networks; and, finally, human in vivo outcomes could be inferred. Furthermore, the pathway and network comparison approaches discussed here that do not depend on evolution-based scoring or phylogenetic information could also be adapted to address another challenge in the new risk assessment paradigm: extrapolating perturbation data from in vitro assays conducted in one cell or tissue type to the cells, tissues, and/ or organs relevant to the critical effect in vivo. The pharmaceutical example of the study of Wy14643 (Rakhshandehroo et al., 2009) Box 1
Uncertainty factors in human health risk assessment
Although risk assessment guidelines and methods vary, the issue of uncertainty pertains regardless. As one example of accounting for uncertainty, the EPA's Integrated Risk Information System (IRIS) applies numerical correction factors to the reference doses (RfDs) and reference concentrations (RfCs) in human health risk assessment. Different uncertainty factors are used to account for: 1) variation in susceptibility among humans (intraspecies uncertainty; see Mortensen and Euling (this issue) for a review of approaches); 2) uncertainty in extrapolating from effects in animal models to effects in humans (interspecies uncertainty); 3) uncertainty in extrapolating from subchronic exposure data to chronic exposure; 4) uncertainty in making inferences based on a lowest-observed-adverseeffect-level (LOAEL) instead of a no-observed-adverse-effectlevel (NOAEL); and, 5) uncertainty due to incomplete information on a chemical (database uncertainty). For the interspecies uncertainty factor, the default value of 10 1 (10X) is composed of a toxicodynamic (TD) portion of 10 0.5 (~3.3×) and a toxicokinetic (TK) portion of 10 0.5 (~3.3×). This uncertainty factor, in any given assessment, can be adjusted if the available data about interspecies differences in TD and/or TK suggest a similarity or difference between animal models and humans (see Fig. 1 ). If data on chemical mechanism of action support a similarity or dissimilarity in humans as compared to the animal test model, then the relevant portion of the interspecies uncertainty factor can be adjusted. For example, in the IRIS Tox Review for ethylene glycol monobutyl ether (EGBE), the TD portion of the interspecies uncertainty factor was reduced to 10 0 (1×) based on data indicating that humans are less sensitive than the test animal for the critical effect (U.S. EPA, 2010).
highlights the utility of both gene-level and pathway-level effects as a method to qualitatively identify species-dependent and speciesindependent gene and pathway effects. With information on multiple species, mechanism of action predictions can be improved for the species of interest. We conclude that comparative genomics data and methodologies will meet a critical need in environmental chemical risk assessment for understanding interspecies differences and for characterizing the uncertainties resulting from extrapolating inferences across species. To make advancements in chemical risk assessment through better understanding interspecies differences in mechanism of action, we propose that research and development efforts focus on current computational methodologies, as compiled and discussed here (see Table 2 in addition to literature cited in the text), and on sources of publicly available genomic information (see Table 1 ), that can be utilized and adapted for the purpose of comparing biological systems and processes across species and for defining toxicityinduced responses in species of interest. Specific areas ripe for further research include the following:
• Chemical case studies applying single gene or protein level comparisons to existing risk assessment processes.
• Chemical case studies based on the research paradigm outlined in Fig. 3 and described herein.
• The development of approaches for quantifying the functional changes and physiological implications associated with detected molecular differences across species in pathway comparison approaches.
• Network comparison methods that are shown to be robust to data gaps and that include performance estimates for more quantitative applications.
• Improved characterization of the differences and similarities in pathway and network models of unperturbed systems among species most relevant to human and ecological risk assessment.
In summary, modeling chemical perturbations in test animals onto pathways and networks that can then be compared to human pathways and networks will bring human health risk assessment one step closer to the NRC's 21st century vision of tethering pathway perturbations directly to human disease instead of basing the mechanism of action on animal models. By querying interspecies comparative network and/or pathway models of chemically-induced perturbations and quantifying the differences, it should then be possible to move closer to developing quantitative measures of interspecies differences for use in risk assessment. , 2006) is modified here by the incorporation of computational comparative genomics approaches. Using rat and human as examples: 1) a rat network perturbation model is developed based on in vivo data; 2) the rat and human networks are computationally compared; 3) differences and similarities found by the interspecies network comparison are tested via human in vitro assays (e.g., primary human cell lines); 4) quantified in vitro perturbations are mapped back to the compared networks; and, 5) human in vivo outcomes are inferred. In addition, rat in vivo assays, driven by network-based hypotheses or otherwise (as represented by the white arrows), can inform the rat network model and the compared network model.
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